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Background: MicroRNAs (miRNAs) are crucial molecules that regulate gene expression and hence pathways that
are key to prostate cancer progression. These non-coding RNAs are highly deregulated in prostate cancer thus
facilitating progression of the disease. Among the many genes that have gained importance in this disease,
Migration and invasion enhancer 1 (MIEN1), a novel gene located next to HER2/neu in the 17q12 amplicon of the
human chromosome, has been shown to enhance prostate cancer cell migration and invasion, two key processes
in cancer progression. MIEN1 is differentially expressed between normal and cancer cells and tissues. Understanding
the regulation of MIEN1 by microRNA may enable development of better targeting strategies.
Methods: The miRNAs that could target MIEN1 were predicted by in silico algorithms and microarray analysis. The
validation for miRNA expression was performed by qPCR and northern blotting in cells and by in situ hybridization
in tissues. MIEN1 and levels of other molecules upon miRNA regulation was determined by Western blotting, qPCR,
and immunofluorescence. The functional effects of miRNA on cells were determined by wound healing cell
migration, Boyden chamber cell invasion, clonal and colony formation assays. For knockdown or overexpression of
the miRNA or overexpression of MIEN1 3′UTR, cells were transfected with the oligomiRs and plasmids, respectively.
Results: A novel miRNA, hsa-miR-940 (miR-940), identified and validated to be highly expressed in immortalized
normal cells compared to cancer cells, is a regulator of MIEN1. Analysis of human prostate tumors and their
matched normal tissues confirmed that miR-940 is highly expressed in the normal tissues compared to its low to
negligible expression in the tumors. While MIEN1 is a direct target of miR-940, miR-940 alters MIEN1 RNA, in a
quantity as well as cell dependent context, along with altering its downstream effectors. The miR-940 inhibited
migratory and invasive potential of cells, attenuated their anchorage-independent growth ability, and increased
E-cadherin expression, implicating its role in mesenchymal-to-epithelial transition (MET).
Conclusions: These results, for the first time, implicate miR-940, a regulator of MIEN1, as a promising novel
diagnostic and prognostic tool for prostate cancer.
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Metastatic progression of prostate cancer is a major
cause of death among men in the United States [1].
Though cancer metastasis is a highly complex multi-step
process facilitated by several key events and molecular
players, the most effective way known to prevent this
progression is by identifying and targeting the various* Correspondence: Jamboor.Vishwanatha@unthsc.edu
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article, unless otherwise stated.genes involved in the process(es) [2,3]. Gene regulation
is tightly controlled in the normal cells, thereby retaining
the homeostatic expression of the appropriate genes for
the functioning of the organism. Deregulation of these
mechanisms in cancer causes the disrupted expression of
the genes, which in turn furthers the cancer progression.
MicroRNAs are a class of endogenous, small non-coding
RNAs, 18 to 22 nucleotides long in their mature form,
which can regulate a set of target genes and result in
translational repression or mRNA degradation depending
on the extent of complementarity and cellular contexttral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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of miRNAs in prostate cancer [6-8]. Many miRNAs have
been implicated as tumor suppressors or oncomiRs
depending on their target(s) and/or the global effects they
have towards cancer progression [9-12]. Though studies
have been performed with respect to certain miRNAs and
their specific targets in prostate cancer [13,14], not much
is known about novel miRNAs targeting the players of
cancer progression that can be used as diagnostic markers
for early detection, or detection of a possible recurrence or
resistance, or therapeutic agents to slow the progression.
Identification of these novel miRNAs and their target gene
(s), and the pathways they affect during cancer progression,
will provide new insights into using them for diagnosis or
determination of specific therapy regimens.
Migration and invasion enhancer 1 (MIEN1), alternately
called C17orf37, C35, RDX12, XPT4, ORB3 or MGC14832,
is located in the 17q12-21 region of the human chromosome
next to HER2/neu in a tail-to-tail arrangement. MIEN1
is abundantly expressed in different stages and grades
of prostate cancer phenotypes when compared to normal
cells and tissues [15]. MIEN1 has also been predicted as a
novel breast cancer biomarker with increased expression
in patients with metastatic progression to lung and liver,
suggesting its importance in cancer metastasis [16].
MIEN1 plays a role in prostate cancer migration and
invasion through enhancement of filopodia formation
by facilitating actin cytoskeletal rearrangement and by
up-regulating the Akt dependent NF-κB target genes
[15,17]. This was further confirmed by the recent determin-
ation of the solution structure of MIEN1 which predicts
that Akt phosphorylation via MIEN1 may be dependent on
the active redox-like motif in the MIEN1 structure [18].
MIEN1 is also post-translationally modified by prenylation,
via GGTase-I, at its C-terminus CVIL motif. Deletion of the
motif not only led to the disruption of MIEN1 membrane
localization and reduced invasive and migratory potential
but also decreased metastasis to the lungs [17]. Although
abrogation of prenylation is a possible targeting strategy,
it cannot be effectively used since it has been proven
that many proteins involved in the regular functioning
of the cell are prenylated, rendering this a very import-
ant modification. Hence, inhibition of prenylation could
negatively impact multiple cellular processes [19]. On the
contrary, since MIEN1 is differentially expressed between
normal and cancer cells and tissues, deciphering the
regulatory mechanism(s) that explain the aberrant expres-
sion of MIEN1 in cancer will enable targeting MIEN1 using
mechanisms that are endogenously prevalent thus forming
an intervention for prostate cancer progression.
In this study, we have identified a novel miRNA,
hsa-miR-940 (miR-940), which targets and regulates
MIEN1 expression. Our study indicates that miR-940
expression inversely correlates with tumor progressionin clinical prostate cancer and the loss of miR-940 in
cancer causes an increased expression of MIEN1 which in
turn enables prostate cancer progression. Ectopic expres-
sion of miR-940 resulted in not only decreased MIEN1 and
its downstream effector molecules, but also reduced the
migratory and invasive potential of the cells. Though the
overall proliferation was unaltered, the ectopic expression
of miR-940 reduced the anchorage-independent growth of
cells, increased E-cadherin and decreased slug expression,
suggesting facilitation of mesenchymal-to-epithelial transi-
tion (MET). Our results demonstrate that miR-940 may be
a useful diagnostic marker as well as a therapeutic agent for
prostate cancer.
Results
MIEN1 is post-transcriptionally regulated by microRNAs
In various androgen dependent and castration-resistant
prostate cancer cells, both MIEN1 mRNA and protein
are highly expressed compared to the immortalized
normal cells of the prostate [15]. Interestingly, in PC-3 cells,
which are androgen receptor negative, though MIEN1
mRNA was expressed, the protein was absent. Hence, we
predicted an active role of post-transcriptional regulation
of MIEN1. Downregulation of microRNA processing
restriction endonucleases, Drosha and/or Dicer [5] using
RNAi resulted in a significant transcriptional up-regulation
of MIEN1 in HEK-293T cells, which do not express MIEN1
mRNA or protein (Additional file 1: Figure S1A). In PC-3
cells, the knockdown of the miRNA maturation enzymes
resulted in an increase in MIEN1 protein expression
by ~4-fold (Additional file 1: Figure S1B). We next per-
formed a microarray analysis to determine the miRNAs
that were differentially expressed between immortalized
normal cells (PWR-1E) and cancer cells (DU-145). The
raw data of the miRNA expression analysis is available at the
NCBI’s Gene Expression Omnibus with GEO accession
number GSE62286. Subsequently, using BLAST and in silico
algorithm-based predictions, we identified three microRNAs,
hsa-miR-324-3p, hsa-miR-221, and hsa-miR-940, that
were differentially expressed between DU-145 and
PWR-1E cells and could potentially target MIEN1 3′
UTR (Additional file 2: Figure S2A and S2B) [20,21].
Using qPCR, the expression levels of these microRNAs
were quantitated as fold change normalized to U6 snRNA
in the different cell lines. A significantly higher expression
of miR-940 was observed in the non-malignant cells,
PWR-1E (~3-fold) and HPV-18C-1 (~7.5-fold), compared
to DU-145 and LNCaP, while, PC-3 showed ~1.5-fold
higher expression of miR-940 (Figure 1A). The expression
of miR-221 and miR-324-3p were neither consistently
higher in the immortalized cells compared to the cancer
cells, nor were they significantly different, together
indicating that miR-940 may be the most relevant regulator
of MIEN1 among the three miRNAs. Next, we performed
Figure 1 miR-940 expression. (A) qPCR shows expression of
the three identified microRNAs: hsa-miR-324-3p, hsa-miR-940 and
hsa-miR-221 normalized to U6 snRNA in immortalized prostate
derived cell lines, PWR-1E and HPV-18C-1 and different prostate
cancer cells, LNCaP, DU-145 and PC-3. (B) Northern Blot depicting
the expression of hsa-miR-940 in immortalized prostate cell line
HPV-18C-1 and prostate cancer cells LNCaP, PC-3 and DU-145.
***P ≤0.001; **P ≤0.01; *P ≤0.05.
Figure 2 MIEN1 expression upon transfection of miRNA mimic
(s) or inhibitor(s) in different cell lines. (A-B) Western blot reveals
levels of MIEN1 in the cell lines transfected with miR-221 (221),
miR-940 (940) or the combination (221 + 940) while untransfected
(Untd), scrambled miR (NT) or transfection reagent (TR) transfected
cells are controls in (A) DU-145 (left), LNCaP (right) and (B) PC-3
(left), PWR-1E (right). GAPDH was used for normalization.
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21nt miR-940 with a biotin-labeled probe. Consistent with
the pattern observed by PCR, the expression of miR-940 in
HPV-18C-1 was significantly higher (Figure 1B).
To validate the regulation of MIEN1 by miRNA(s), we
ectopically overexpressed the miRNA mimics or inhibitors
in the various cell lines. We observed a decrease in the
expression of MIEN1 protein by ~3- and ~2-fold in
DU-145 (Figure 2A, left) and LNCaP (Figure 2A, right)
cells, respectively, when transfected with miR-940 mimic.
Conversely, inhibiting the endogenous miR-940 in PC-3
(Figure 2B, left) and PWR-1E (Figure 2B, right) using
anti-miR-940 increased the MIEN1 protein by ~4-
and ~2-fold, respectively. Since miR-221, was significantly
higher in PC-3 compared to DU-145, we also ectopically
expressed miR-221 mimic in DU-145, together with
miR-940, or by itself, and observed a decrease in theMIEN1 protein (Figure 2A, left). But, when we inhibited
miR-221 alone in PC-3, we did not see any increase in
MIEN1 (Figure 2B, left), implying miR-940 to be a more
potent regulator of MIEN1 than miR-221. Together, these
results demonstrate that miR-940 is differentially expressed
between normal and cancer cells and that it targets and
regulates MIEN1 expression. Hence, from here on, we
only examined the relevance and role of miR-940 in
key processes of prostate cancer progression.
Loss of microRNA, hsa-miR-940, is an indicator of prostate
cancer
The expression levels of miR-940 were next examined
in a clinical sample cohort of prostate cancer patient
tissues by in situ hybridization with miR-940 or
scrambled miRNA probe as described in the methods.
The prostate cancer (PCa) and matched normal (MN)
tissues were independently scored and graded (based on
the corresponding H&E performed) by two pathologists;
only those that matched were used to draw conclusions.
In two specific patients who had undergone surgical resec-
tion via radical prostatectomy, we observed that miR-940
expression was high in normal glands and benign prostatic
hyperplasia with the expression being lower in infiltrating
prostate cancer cells (Figure 3A and B). In the small pilot
cohort of 15 samples, we observed that the miR-940
expression was higher in the matched normal sections
in contrast to the low expression in the tumor cells
(represented in Figure 3C). Correspondingly, the expres-
sion of MIEN1 was relatively higher in the cancer sections
compared to the normal (represented in Figure 3C). We
observed that the miR-940 staining intensity was high
Figure 3 miR-940 expression in human prostate cancer and normal tissues. (A-B) In situ hybridization of the scrambled miR (miR-Scr) or
miR-940 and H&E staining in normal/benign glands compared to the infiltrating tumor. (C) H&E staining (i), miR-940 (ii), and MIEN1 (iii) in cancer
(top) and matched normal (bottom) tissues with miR-Scr (iv), and IgG control (v) representing the negative controls. (D) ~87% (n =13) tumor
shows low (intensity ≤3) expression of miR-940 compared to ~80% (n =12) of the matched normal tissue with higher (intensity >3) miR-940
expression; conversely, ~13% (n =2) of the tumor expressed more (>3) miR-940 compared to lower expression (≤3) in ~20% (n =3) of the matched
normal (n =15). Scale bar: 100μm.
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out of 15 tumor sections showed staining intensity of
4. Complementarily, 3 of the 15 normal tissues showed a
staining intensity of 3 as opposed to tumors exhibiting
lower intensities (1, 2, and 3) in 13 of the cases (Figure 3D).
Additionally, to determine if miR-940 levels vary in be-
nign prostatic hyperplasia (BPH) and metastatic pros-
tate tumors (Mets), we performed in situ hybridization
and immunohistochemistry and quantified the staining
intensities of miR-940 as well as MIEN1 in these tissues.
The representative images of the staining pattern are
provided in Additional file 3: Figure S3A. As expected,
in the small cohort of samples, a statistically signifi-
cant difference was observed in the expression levels
of both miR-940 as well as MIEN1 between the various
groups. While there were higher levels of miR-940 in
the BPH and MN tissues, with a reduction in PCa,
the levels were minimal in Mets (Additional file 3:
Figure S3B,i). Conversely, the highest expression of
MIEN1 was observed in the metastatic tissues (Mets)
followed by PCa tissues, with lowest expression in the
BPH and MN tissues (Additional file 3: Figure S3B,ii).
Together, our results indicate that even in a clinical
setting (supported by the in vitro data), miR-940 expressionis consistently higher in the normal tissues as opposed to
the tumor cells.
MIEN1 is a direct target of miR-940
Next, we wanted to determine if the MIEN1 mRNA
stability was altered directly by miR-940. DU-145 cells
were transfected with either miR-940 or the control
miRNA and treated with Actinomycin-D (Act-D). The
half-life of MIEN1 mRNA was observed to be ~6 hours
with almost no detectable mRNA in 12 hours after treat-
ment with Act-D in miR-940 transfected cells compared to
the control transfected cells (Figure 4A), thus indicating that
miR-940 decreases MIEN1 mRNA levels significantly.
We then examined if miR-940 directly binds to the
MIEN1 3′UTR using a luciferase plasmid cloned with
MIEN1 3′UTR. Binding of the miRNA directly to the
3′UTR of MIEN1 is expected to inhibit the luciferase
luminescence compared to the luminescence when
the miRNA is unable to bind to the empty luciferase
vector control or the MIEN1 3′UTR containing a
mutation in the binding site for miR-940. When MIEN1
3′UTR containing luciferase plasmid (MIEN1WT) was
co-transfected with miR-940 in DU-145 (Figure 4B) cells,
there was ~2-fold reduction in luminescence as opposed
Figure 4 miR-940 directly binds to MIEN1. (A) MIEN1 mRNA level expressed as fraction of the initial value (T0) plotted over time, upon
10 μg/ml Actinomycin-D treatment following transfection with the Pre-miR-NT or Pre-miR-940 for 48 hours in DU-145. (B-D) Luciferase Reporter Assay
showing relative luminescence upon co-transfection of miR-940 (right) or Pre-miR-NT (left) with either empty luciferase vector (Vec) or MIEN1 3′UTR
luciferase vector (MIEN1WT / MIEN1Mut) in DU-145 (B), LNCaP (C) or PC-3 (D) respectively. ***P ≤0.001; **P ≤0.01.
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or mutant MIEN1 3′UTR (MIEN1Mut) and miR-940
co-transfections. Additionally, co-transfection of the
miR-NT with either the Vec or the MIEN1WT plasmid did
not show any significant changes in the luminescence
in DU-145. Similarly, in LNCaP cells, miR-940 co-
transfection with MIEN1WT plasmid showed a reduction
in luminescence compared to the controls (Figure 4C). In
PC-3 cells, which express some endogenous miR-940,
co-transfection of MIEN1WT plasmid with either the
miR-940 mimic or the control miRNA showed signifi-
cantly lesser luminescence (Figure 4D) compared to
the Vec plasmid co-transfections. Since we observed
that the ectopic overexpression of miR-940 did not
have a higher reduction in luminescence compared to
the miR-NT co-transfections, it is possible that the
regulation of MIEN1 in PC-3 cells may not necessarily
involve mRNA degradation; it may just be translational
repression. This conforms to our earlier findings that
though the MIEN1 mRNA is exhibited in PC-3, pro-
tein is very low to negligible. Together, the luciferase
assays provide direct evidence of miR-940 – MIEN1
mRNA interaction.miR-940 affects target genes in a cellular context
dependent manner
Since it is known that silencing MIEN1 decreases NF-κB
mediated downstream effectors MMP-9, uPA and VEGF
[15], we examined if ectopic overexpression of miR-940
had the same effect on downstream effectors of MIEN1.
Upon overexpression of miR-940 in DU-145, a decrease
was observed in MMP-9, uPA and VEGF, along with pNF-
κB S536 (an indicator of nuclear NF-κB that is responsible
for the transcription of target genes) at the protein level
(Figure 5A,i) compared to the control. Reductions
from ~2- to 3-fold in MMP-9, uPA and VEGF transcripts
in DU-145 (Figure 5A,ii) further confirmed the inhibition
of the NF-κB mediated transcriptional activity. Conversely,
the knockdown of endogenous miR-940 in PWR-1E
increased protein (Figure 5B,i) and transcript levels
(Figure 5B,ii) of MMP-9, uPA and VEGF.
Interestingly, the effects observed with PC-3 were
quite unique. It is well known that the miRNA regulation
can result in either mRNA degradation or translational
repression of the target [22,23]. Though PC-3 has an
increased level of MIEN1 protein upon treatment with
anti-miR-940 (Figure 2B, left), there was no increase in
Figure 5 miR-940 targets MIEN1 and affects MMP-9, uPA and VEGF expression in a cellular context-dependent manner. (A-B) Expression
of the downstream targets of MIEN1 upon transfection of Pre-miR-NT or Pre-miR-940 in DU-145 (A) and Anti-miR-NT or Anti-miR-940 in PWR-1E
(B) at both the translational and transcriptional levels as shown by western blotting (A,i, B,i) and qPCR (A,ii, B,ii) respectively. (C-D) qPCR showing the
expression of MIEN1 and the effectors upon transfection with Anti-miR-940 in PC-3 (C) and with Pre-miR-940 in PC-3 (D).***P ≤0.001; **P ≤0.01; *P ≤0.05.
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overexpression of miR-940 in PC-3 resulted in a decrease
in MIEN1 and its downstream targets, MMP-9, uPA
and VEGF compared to the control at the mRNA
level (Figure 5D), indicating that the mechanism by
which miR-940 affects MIEN1 mRNA is dependent
on the amount of miRNA present, which in turn is
dependent on the cell type being considered and thus
the general cellular context.
miR-940 attenuates the migration and invasion of
prostate cancer cells along with inhibiting their
anchorage-independent growth potential
MicroRNAs have multiple targets; hence, the overall effects
of a particular microRNA on global cellular functions may
vary depending on the regulation of the various targets and
their combined implications [24,25]. Migration and inva-
sion are key processes that facilitate cancer progression andMIEN1 is known to increase these processes [2,15]. Since,
MIEN1 is one of the direct targets of miR-940, we sought
to determine if the ectopic overexpression of miR-940
could attenuate these processes, independent of the effect
that miR-940 may have on other transcripts. A scratch
wound healing migration assay showed that lesser migra-
tion (~0.54-fold) was observed in DU-145 cells treated
with miR-940 compared to the non-targeting control
24 hours after the initial scratch (Figure 6A) while this
effect was rescued partially (~0.86-fold) when the cells
were transfected with MIEN1 ORF plasmid which was
non-targetable by miR-940 since it lacks the 3′UTR.
Knockdown of the miR-940 using anti-miR-940 in
PC-3 resulted in ~1.8-fold increase in its migratory po-
tential (Figure 6B). To investigate whether miR-940
affects the cell viability, MTT assays were performed
with ectopic expression of miR-940 mimic in DU-145
and anti-miR-940 in PC-3 cells. Also, in DU-145 these
Figure 6 miR-940 affects the cellular migratory and invasive potential. (A) Migration of DU-145 upon transfection with either Pre-miR-NT,
Pre-miR-940 or MIEN1 ORF with miR-NT or miR-940 depicted by a wound healing assay (left) and quantified as a percentage of the wound area
closed (right, top) after 24 hours; (right, bottom) Western blotting to show MIEN1 expression in the different cells. (B) Representation (left) and
quantification (right) of the migratory potential of PC-3 cells upon transfection with Anti-miR-NT or Anti-miR-940, 24 hours after making a wound.
(C-D) Representation (top) and quantification (bottom) of the invasive potential of DU-145 (C) and PC-3 (D) cells as determined by the Boyden
chamber matrigel invasion assay when transfected by miRNA mimic and inhibitor respectively. (E) Cell cycle analysis showing the percentage of
the cell population in the Pre-miR-NT, Pre-miR-940, siNT and siMIEN1 transfected DU-145 cells. ***P ≤0.001; **P ≤0.01.
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down of MIEN1 directly with siRNA. Though transfection
with anti-miR-940 in PC-3 cells showed a statistically
significant decrease in cell viability after 48 hours
(Additional file 4: Figure S4A) this was only a 15% change
and the effect was abrogated after 72 hours. No signifi-
cant differences were observed in the cell viability after
48 or 72 hours of transfection in DU-145 (Additional file
4: Figure S4B), proving that neither miR-940, nor its
target MIEN1, has any dramatic effect on cell viability.
Next, the invasive potential of the cells was determinedusing miR-940 mimic or inhibitor transfected DU-145
or PC-3 cells through the transwell matrigel invasion
assay system. The ectopic expression of miR-940 de-
creased the invasiveness of DU-145 -5-fold (Figure 6C),
which was abridged by reintroduction of non-targetable
MIEN1 ORF construct and conversely, the invasiveness of
PC-3 was ~3.5-fold higher upon inhibition of endogenous
miR-940 by anti-miR-940 (Figure 6D). Furthermore, to
ensure that the effects observed on migration and invasion
are a true result of these processes, cell cycle analysis was
performed with DU-145 cells transfected with miR-940
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significant differences between the different populations
of DU-145 cells (Figure 6E). Taken together, these results
show that miR-940 inhibits both the migratory and inva-
sive potential of the cells without affecting cell viability
and that these responses are, at least partially, mediated
through its regulation of MIEN1.
The ability of the cancer cells to adhere and grow by
anchorage-dependent and -independent mechanisms is
very important to determine their clonogenic ability and
hence their potency to evade cell death and finally
metastasize [26]. We observed that the DU-145 cells
transfected with miR-940 formed smaller, smooth edged
colonies compared to bigger, disseminated colonies formed
by the control miR transfected cells, after 12 days
(Figure 7A, left and Additional file 5: Figure S5A)
under anchorage-dependent conditions. The total number
of individual colonies remained unchanged between the
treatments (Figure 7A, right). Conversely, the soft agarFigure 7 miR-940 alters the anchorage-dependent and -independent
of colonies formed by Pre-miR-NT or Pre-miR-940 transfected DU-145 cells
colony formation assay shows the colonies in the agar (left) and their quan
western blotting (D) show the expression and localization of various prote
bar: 20μm. **P ≤0.01.colony formation assay demonstrated that the anchorage-
independent growth potential of the miR-940 transfected
cells was highly hindered (~8-fold) compared to the
control transfected cells after 12 days (Figure 7B).
Dissemination of the cells is an indicator of the cells
undergoing epithelial-to-mesenchymal transition (EMT),
a phenomenon crucial to the initial detachment of the
cells from the tumor site, leading to the invasion and
migration of cells, and finally resulting in progression of
cancer [27]. The considerable morphological difference
observed in terms of compactness of the colonies between
cells transfected with miR-940 and miR-NT suggested
loss of the ability of the miR-940 transfected cells to
undergo EMT. To further confirm the possibility of the
involvement of miR-940 in hindering EMT, we performed
immunostaining for E-cadherin, a cell adhesion marker
that is downregulated if the cells undergo the process of
EMT, and Vimentin, a mesenchymal marker. Our results
show an increase in E-cadherin in miR-940 transfectedgrowth of DU-145 cells. (A) Morphology (left) and number (right)
after 12 days on tissue culture treated adherent plates. (B) Soft agar
tification (right) after 12 days. (C-D) Immunofluorescence (C) and
ins upon overexpression of Pre-miR-940 compared to Pre-miR-NT. Scale
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along with disruption of its membrane localization
(Figure 7C and D). Additionally, the mRNA expression
of Slug, a transcriptional regulator of E-cadherin,
decreased in miR-940 transfected cells compared to the
control (Additional file 5: Figure S5B). In PC-3 cells,
transfection of the miR inhibitor caused a decrease in
E-cadherin transcript levels (Additional file 5: Figure S5C).
Together, this suggests the possible involvement of
miR-940 in MET, the reverse process of EMT.
Discussion
MIEN1, a novel gene in the 17q12 region of the human
chromosome, is differentially expressed between cancer
and normal cells and tissues [16]. Previous studies indicate
that MIEN1 plays an important role in prostate cancer
progression [15,17]. In this study, we show that MIEN1
undergoes post–transcriptional regulation by miR-940.
Our data show that miR-940 decreases the migratory and
invasive potential of prostate cancer cells along with facili-
tation of MET. Also, decreased expression of miR-940 in
prostate cancer specimens proves the clinical relevance of
this miRNA, leading to our belief that miR-940 is a potential
diagnostic marker and therapeutic agent.
The use of miRNAs for therapy and/or diagnosis of
cancer is currently under consideration due to the accu-
mulating evidence demonstrating their extensive deregula-
tion in many cancers, including prostate cancer [7,28-30].
MiRNA mediated regulation of a target gene depends on
multiple parameters including: 1) properties of miRNA
responsive elements, such as the degree of complementarity
and accessibility; 2) number of miRNAs that could target a
single transcript; 3) expression of competitive endogenous
mRNAs for a miRNA in a specific cellular context; 4)
stimulus for the miRNA transcription/splicing and hence
expression and stability; and, 5) other factors influencing
the target mRNA stability and expression [22-25]. Careful
examination of the degree to which a gene is regulated by a
miRNA and the overall effects of the miRNA mimic or
inhibitor, are essential to determine the global role of the
miRNA in any cellular context.
The distinct difference in the expression of MIEN1
and lack of protein despite mRNA expression in PC-3
cells directly implied involvement of post-transcriptional
regulation. Our experiments confirmed that MIEN1 is
indeed regulated by miRNA and led to the identification
and validation of miR-940. Alterations in mRNA half-
life in the presence of the miRNA elucidated the ef-
fect of miR-940 on MIEN1 mRNA stability. Furthermore,
using luciferase assays, we ascertained that miR-940 binds
directly to the 3′UTR of MIEN1 to cause its suppression.
MIEN1 is minimally expressed in several normal tissues
compared to its overexpression in cancer [16]. Its proximity
to the HER2/neu locus on chromosome 17 explainsits frequent amplification (in 79% of breast cancers)
with HER2 amplicon [31]. A recent study using a set
of eight genes, including MIEN1, revealed a moderate
response to adjuvant Trastuzumab therapy even in HER2
negative breast cancer, confirming the importance of
this gene in responses to neo-adjuvant therapies [32].
Katz et al. have shown that the overall survival of
breast cancer patients is low in cases where MIEN1 is
highly expressed while lower expression indicates better
prognosis [33]. It is well known that prostate cancer-related
deaths are due to metastasis rather than the presence of a
primary tumor alone. Metastasis is a complex process
involving multiple intermediate steps, from detachment of
the cells at the primary site to formation of secondary
tumor. The tumor cells evade the resistances faced at every
step by different mechanisms [2,3]. Our previous study has
shown that cells overexpressing MIEN1 have a higher
metastatic potential, though it does not mean quicker onset
or initiation of the tumor [17]. We have also previously
shown that MIEN1 increases phosphorylation of Akt
causing the translocation of NF-κB to the nucleus
and then transcriptionally activating downstream effectors
like MMP-9, uPA and VEGF [15]. These proteases and
angiogenic factors are known to cleave extracellular
matrix, hence facilitating migratory and invasive potential
of the cells. Taken together, these studies confirm that
MIEN1 plays an important role in the progression of
cancer rather than in the initiation of the tumor. Here, we
show that upon ectopic reintroduction of miR-940, the
mRNA as well as protein levels of the effector molecules
decrease in DU-145. Conversely, downregulation of the
miRNA using inhibitors increases the effector molecules
in PWR-1E. Hence, miR-940, indirectly through MIEN1,
is capable of decreasing expression levels of specific
proteins that facilitate migration and invasion.
It is known that miRNAs can affect expression by
causing mRNA degradation through complex formation
with RNA-induced silencing complex or by repressing
the translation of the mRNA, thus inhibiting formation
of the protein [22]. The degree of complementarity and
the competitive endogenous mRNAs determine the
fate of the miRNA-mRNA complex [24]. Here, we see
that miR-940 expression is highest in the immortalized
PWR-1E cells, followed by PC-3 cells and lowest in
DU-145. In addition to this expression pattern, our data
prove that inhibition of miR-940 has different effects on
MIEN1 mRNA and protein levels in the various cell lines.
This implies that the inhibition of MIEN1 using miR-940
affects MIEN1 in a manner dependent on not only the
cellular context (other competitive endogenous mRNA in
the specific cells) but also on the endogenous miRNA
levels. While in PWR-1E, the endogenous miR-940
potentially degraded MIEN1 mRNA; the overexpression
of anti-miR-940 resulted in attenuation of MIEN1 mRNA
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mRNA and protein levels. Conversely, the loss of the
endogenous miR-940 in DU-145 possibly led to the
overexpression of both MIEN1 mRNA and protein;
and hence ectopic overexpression of the miR-940, as
we have observed, caused MIEN1 mRNA degradation
resulting in significant depletion of both transcript
and protein levels. However, in PC-3, where MIEN1
mRNA is expressed but protein is low, inhibition of
miR-940 with anti-miR-940 resulted in no further increase
of MIEN1 mRNA but only increased MIEN1 protein.
Additionally, the inhibition of endogenous MIEN1
mRNA with ectopic miR-940 in PC-3 decreased MIEN1
transcript. Together, this indicates that the endogenous
miR-940 was causing translational repression of the
MIEN1 mRNA rather than degradation in PC-3. Thus,
these results show that while miR-940 causes MIEN1
mRNA degradation in DU-145 (ectopic and conceivably
endogenous expression) and PWR-1E (endogenous), it
causes translational repression of MIEN1 in PC-3 cells
(endogenous). The unique ability of this miRNA to
perform both mRNA degradation as well as translational
repression of the same target depending on the levels
of the miRNA and the cellular context seems like a
novel finding.
MicroRNAs could target multiple transcripts, thus
eliciting a response which is dependent on the combined
effects on its targets [24]. A recent study implied that
miR-940 could be one of the regulators of alpha-1
antitrypsin [34]. Loss of this serine proteinase inhibitor
results in increased risk of lung and liver cancers while its
elevated serum levels are associated with prostate cancer
[35], supporting our hypothesis that the miR-940 is
lost in cancer cells and tissues. In our study, we performed
experiments to determine the effects miR-940 would have
on migration and invasion, thus delineating the mechanism
by which miR-940 could affect cancer progression,
based on its regulation of MIEN1, a validated player
in the regulation of prostate cancer migration and invasion.
We observed a decrease in both the migratory and invasive
potential of the cells upon ectopic expression of the
miRNA and the converse was seen when the miRNA was
inhibited. Additionally, these effects were negated upon re-
introduction of the non-targetable MIEN1 into the system.
Hence, we are the first to report that miR-940 inhibits
prostate cancer migration and invasion, at least in part via
MIEN1 along with other probable targets. The ability of
cells to form disseminated colonies without attaching to
the substratum is very important to determine the tumori-
genicity of the cells [26,27,36]. Previous reports indicate
that MIEN1 enhances EMT in breast cancer [33]. Our
study demonstrates that miR-940 completely inhibits this
ability of prostate cancer cells along with promoting MET
by increasing the E-cadherin and decreasing Vimentinexpression. The decrease in slug, an indicator of cells
losing their mesenchymal trait [37], was also observed in
corroboration. Since EMT is a very complex yet important
process in prostate cancer progression [38-40], further
investigation to identify the exact mechanism by which
miR-940 facilitates this transition is required. It is also
important to determine the different global pathways
and the proteins that may be altered by miR-940 that
culminates in miR-940 mediated inhibition of prostate
cancer progression. Since miR-940 is a very novel
miRNA whose function has never been validated or
reported in any pathway before, in our study we used
a set of common genes predicted to be targets of
miR-940 by multiple algorithms. The extensive gene
list was then categorized into known and validated
pathways using the Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway mapping and annotation table
available in the Database for Annotation, Visualization
and Integrated Discovery 6.7 (DAVID 6.7) [41,42]. The
preliminary examination of the results obtained from
DAVID was then represented as a function of the
number of genes involved within the pathway that
could be downregulated by miR-940 (Additional file 6:
Table S1A), and further classified based on the signifi-
cance of the overall pathway alteration (Additional file 6:
Table S1B). Interestingly, the pathway with most number
of genes affected was a global pathway in cancer. Also,
many other predictions within the threshold set indicated
the regulation of other pathways considered important in
cancer. Thus, miR-940 may be eliciting the responses we
have observed via other targets in addition to MIEN1 and
this needs further validation.
Studies over the past decade have proven beyond
question that in addition to understanding the regulation
of pathways, early stage identification and targeting of
prostate cancer is of primary importance in order to prevent
metastasis of the disease. Use of deregulated miRNA
profiles is currently under consideration to enable the
advancement of detection and diagnoses [10,28-30].
We have seen that miR-940 expression is high in the
normal and benign glands in tissues obtained from
patients who have undergone prostatectomy compared to
lower expression in the tumor. Associating the expression
patterns of miR-940 and MIEN1 with the early detection
and differentiation of the indolent from aggressive disease
will be a valuable tool that could be used clinically
for early prostate cancer detection. Use of circulating
miRNAs from the serum is not only minimally invasive
but also reliable since miRNAs are highly stable in the
blood and hence can be used as potential biomarkers
[43,44]. Apart from the potential use of miR-940 in tissues
and serum as a biomarker along with the expression of
MIEN1, studying the regulation of miR-940 itself may
provide more insight into the mechanism of its expression
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our results, indicates facilitation of cancer progression.
Examination of miR-940 promoter exhibited high possibil-
ity of methylation and this warrants further investigation.
Conclusions
This study is the first to identify miR-940 as a novel
regulator of MIEN1, a molecule involved in prostate
cancer progression. With our in vitro studies, we estab-
lished the role of miR-940 in several key processes of metas-
tasis; including migration, invasion, anchorage-independent
growth and EMT. Additionally, with the clinical investiga-
tions in a small sample cohort, we demonstrated that
miR-940 expression is low in tumor, contrary to
MIEN1 expression pattern. Together, this could be an
important regulator-target combination to study and
be used as prognostic indicators for prostate cancer.
Materials and methods
Cell lines, cell culture, siRNA, miRNA and plasmid
transfections
Human prostate carcinoma cells DU-145 (ATCC HTB-81),
PC-3 (ATCC CRL-1435), and LNCaP (ATCC CRL-1740)
were maintained in RPMI 1640 media supplemented with
10% fetal bovine serum (Life Technologies). Immortalized
non-tumorigenic prostate epithelial cell line HPV-18C-1
(a kind gift from Dr. Jhong S. Rhim, Frederick Cancer
Research and Development Center, National Cancer
Institute, Frederick, MD) and PWR-1E (ATCC CRL-11611)
were maintained in Keratinocyte-SFM (Life Technologies)
supplemented with bovine pituitary extract (25 μg/ml) and
recombinant epidermal growth factor (0.15 ng/ml). Cells
were cultured at 37°C with 5% CO2. The cell lines were
authenticated according to “Authentication of Human Cell
Lines: Standardization of STR Profiling” using GenePrint®
10 System (Promega); all cell lines and their passages
exhibited >80% match to the initial cell line STR profile
provided by ATCC [45]. The smart pool siRNAs were
obtained from Dharmacon (Thermo Fisher Scientific),
while the precursor and inhibitor miRNA oligos (Pre- and
Anti-miR) were purchased from Ambion (Life Technologies).
The final concentration of the miRNA oligos used for
transfection was determined by preliminary concentration-
dependent studies and remained constant for all the experi-
ments. Plasmid transfections were performed using
Lipofectamine 2000 while Lipofectamine RNAiMAX was
used for RNAi transfections, performed according to the
manufacturer’s protocols (Life Technologies).
Antibodies and reagents
The following antibodies and reagents were used: Mouse
monoclonal and mouse polyclonal MIEN1 (Abnova;
antibody specificity tested and proven in previous
studies[15,17]), rabbit polyclonal MIEN1 (Life Technologies;antibody specificity tested in previous studies[15]), mouse
monoclonal GAPDH (Santa Cruz Biotechnology), rabbit
monoclonal pNF-κB p65 S536 and rabbit polyclonal
MMP-9 (Cell Signaling Technology), mouse monoclonal
VEGF and uPA (R&D Systems), mouse monoclonal Alexa
Fluor 594 conjugated Phalloidin (Life Technologies),
mouse monoclonal E-cadherin (BD Biosciences), Vimentin
(supernatant developed in mouse and tested against
human antigen, Developmental Studies Hybridoma Bank),
anti-mouse and anti-rabbit IgG (Promega), AlexaFluor 488
goat anti-mouse IgG and AlexaFluor 594 goat anti-mouse
IgG (Life Technologies) sheep anti-DIG-AP antibody and
NBT-BCIP ready-to-use tablets (Roche), sheep serum
(Jackson ImmunoResearch), rabbit IgG, BSA, levamisole
hydrochloride, Tris-HCl (pH 7.4), nuclease free water, SSC
buffer, Xylene, Tween-20, Nuclear Fast Red, Hematoxylin
and Eosin (Sigma-Aldrich) and Permount and PBS
(Thermo Fisher Scientific).
Bioinformatics and microarray analysis
In silico analyses were performed to determine the putative
miRNAs that could target MIEN1. The software programs
used included miRANDA [20], PicTar [46], miRBase [47]
and TargetScan [21], all of which used the 3′UTR as the
target region to determine miRNA recognition elements
and provided scores to determine predictive values.
For microarray based hybridization, DU-145 and
PWR-1E cells were trypsinized, spun down, washed with
sterile PBS and frozen immediately at -80°C. The
samples were de-identified and shipped to LC Sciences
(Houston, TX) for microarray hybridization. In brief, total
RNA was isolated from the cells and enriched for small
RNA (<300nt). Subsequently, the small RNAs were 3′
extended with polyA tail and an oligonucleotide tag was
ligated to it for fluorescent dye staining (Cy3). The
samples were then hybridized to the probe set on the plate
(probes consisted of sequences complementary to miRNA
from miRBase as well as the specially requested custom
probes). After hybridization, the miRNA expression was
detected by fluorescence labeling using tag-specific dye.
Images collected were analyzed using Array-Pro image
analysis software. Data analysis involved subtraction of the
background along with normalization. Paired t-test results
were provided for further interpretation and study.
qPCR
Total RNA was isolated from the cell lines using TRIzol
(Life Technologies) and quantified. Equal amount of
RNA was used for the one-step or two-step qPCR
performed using the Superscript III SYBR Green qRT-PCR
kits, according to manufacturer’s instructions (Life Tech-
nologies). For miRNA, PCR was performed using NCode
VILO miRNA cDNA Synthesis and EXPRESS SYBR
GreenER miRNA qRT-PCR Kits (Life Technologies),
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(sequences provided in the Supplementary materials and
methods; Additional file 7) were designed using Primer 3
[48] and synthesized by Integrated DNA Technologies
(Coralville, IA). PCR was performed using Realplex2
Mastercycler ep gradient S thermal cycler (Eppendorf).
Western blotting
Western blotting was performed according to standard
protocols. Briefly, total protein was isolated using NP-40
lysis buffer and estimated using the standard Micro BCA
Protein Assay Kit (Pierce Biotechnology). NuPAGE®
Novex® 4-12% Bis-Tris Gels were used and the samples
were transferred onto nitrocellulose membranes using
an iBlot (Life Technologies). Membranes were blocked
in 5% non-fat dry milk or 1% BSA prior to antibody
subjection. The chemiluminescent reaction was captured
by the AlphaImager (ProteinSimple) and bands were
analyzed using ImageJ software [49].
Northern blotting
Northern blotting was performed using miRNA Northern
Blot Assay Kit and custom ordered biotin-labeled
miR-940 and U6 control probes (Signosis) with one
microgram of total RNA from each cell line, according to
manufacturer’s instructions.
RNA stability assay
Cells were transfected with the precursor oligomiRs and
48 hours after transfection, treated with 10 μg/ml Act-D
(Sigma-Aldrich). RNA was isolated at several time points
and quantified. Equal amounts of RNA were used to run
qPCR to determine MIEN1 levels.
Luciferase reporter assay
Cells were transfected with 3′UTR luciferase constructs
(Origene) - Empty Vector (Vec) or 3′UTR-MIEN1
(MIEN1WT / MIEN1Mut) and miR-940 or miR-NT in dupli-
cate. Luciferase assay was performed using the Luciferase
Assay System (Promega) according to manufacturer’s in-
structions and luminescence read using Synergy2 Alpha
Microplate Reader (BioTek).
Migration assay
For migration assay, a scratch was made in a monolayer
of transfected cells using a pipet tip, 48 hours after
transfection. Fresh media was added immediately to
remove the floating cells and the scratch and surrounding
cells were imaged at T0 (immediately after scratching).
Images were captured at specific time points from at
least ten independent fields to determine the wound
closure. Migration was calculated as a percentage of
the area covered by the cells compared to the original
wound area.Invasion assay
Invasion assay was performed with transwell invasion
assay inserts and 24-well plates (BD Biosciences) according
to manufacturer’s protocol. In brief, cells were transfected
with the miRNA oligomiRs and the inserts were coated
with Matrigel (BD Biosciences). Cells were trypsinized 48
hours after transfection and 500 μl of the cell suspension
(concentration of 5 X 104 cells/ml) was plated in duplicate
in Matrigel-coated and non-coated transwell inserts with
fetal bovine serum as a chemoattractant in the bottom
well. The lower side of the transwell membranes were fixed
and stained with 0.05% crystal violet 24 hours after plating.
Fold change in invasion was calculated as a ratio of cells
invading the Matrigel matrix-coated insert membrane
to the cells migrating through the uncoated membrane.
The invasion of no-targeting miRNA transfected cells
was considered as 1 and the fold change was calculated
accordingly.
Flow cytometry
DU-145 cells were transfected with miRNA mimics
or siRNA against MIEN1 and subjected to cell cycle
analysis using Propidium Iodide in a Beckman Coulter
Cytomics FC 500 Flow Cytometer. In brief, transfected
cells were trypsinized, washed with PBS, counted and
resuspended to a concentration of 1.5 × 106cells/ml,
72 hours after transfection. Cells were fixed in cold
ethanol at 4°C, overnight. After washing with PBS and
centrifuging the suspension, the pellet was resuspended in
PI with RNaseA and incubated at 4°C for about 3 hours in
the dark before analysis.
Anchorage-dependent and -independent growth assays
For the anchorage-dependent clonal assay, cells were
treated with precursor miR-NT/940 for 48 hours and
seeded (2500 cells per well) on polystyrene coated 6-well
plates. After 12 days, the colonies were fixed and stained
with 0.05% crystal violet or subjected to immunofluores-
cence. Only individual colonies (>50 cells per colony) were
considered to obtain the average number of colonies for
each treatment.
For anchorage-independent colony formation assay,
cells were treated with precursor miR-NT/940 for 48 hours
before re-plating (5000 cells per ml per well) on soft agar
(cells in 2X media:agar = 1:1). Colonies were stained with
0.05% crystal violet and counted after 12 days of incubation
in soft agar.
Immunofluorescence and confocal microscopy
Cells were transfected, as described in anchorage-
dependent assay, plated on coverslips to at least 90%
confluence, fixed with 4% paraformaldehyde, perme-
abilized with 100% methanol, blocked with 1% BSA
and stained for the specific proteins. The coverslips
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Fisher Scientific) and imaged using a Zeiss confocal
microscope LSM 510 under 40X, water immersion
objective. At least five independent fields per experi-
ment were captured. The images were analyzed with LSM
software and the predominant pattern is represented here.In situ hybridization and immunohistochemistry
Archived paraffin-embedded prostate tumor with matched
normal and tumor infiltrating normal gland tissue sections
from multiple patients were collected under the approval
of the Institutional Review Board at the site. The study
protocol was approved by the Institutional Review Board
at UNT Health Science Center. The anatomic pathologists
independently read the slides and graded the Hematoxylin
& Eosin (H&E) stained sections to provide scores
(1-5; based on predominant primary Gleason pattern)
and read the hybridized sections to determine miR-940
intensity scores (1-5; 1 being basal to very low to 5 being
high intensity) for the matched normal and prostate
progression sections; a chromogenic assay based on
DIG labeled probes detected by alkaline phosphatase
conjugated anti-DIG and NBT-BCIP substrate was
used for miR-940 staining. The Exiqon (Denmark)
miRCURY LNA™ microRNA ISH Optimization Kit
(FFPE) was used to standardize and perform in situ
hybridization, using scrambled miRNA and the 5′- and
3′-DIG double labeled miR-940 probes. The extent
of Proteinase-K treatment, the hybridization time and
temperature, and incubation with the substrate were all
standardized for the probes. Correspondingly, MIEN1
and isotype-specific rabbit IgG antibodies were used
for immunohistochemistry that was performed on the
serial sections according to standard protocols. The
images were captured as described previously [50].
ImageJ analysis of the staining intensities in the various
tissues was performed with the “Colour Deconvolution”
plugin [49].Statistical analyses
The results were represented as mean ± S.E.M of inde-
pendent experiments. The p-value was calculated accord-
ing to Student’s t-test when comparing two groups
using GraphPad P-value calculator. Multiple groups
were compared by one-way ANOVA, when necessary,
followed by pair-wise comparisons with post-hoc test.
The differences were considered significant if p-value
was at least ≤0.05.Consent
The patients provided consent for the use of the tissues
for research and publication.Additional files
Additional file 1: Figure S1. Post-transcriptional regulation of MIEN1.
(A) Drosha, Dicer and MIEN1 expression levels upon knockdown of
miRNA maturation enzymes, Drosha and/or Dicer compared to control
siRNA (NT) in HEK293T as shown by qPCR. (B) Fold change in MIEN1
protein levels upon knockdown of miRNA maturation enzymes, Drosha
and/or Dicer compared to control siRNA (NT) in PC-3. **P ≤0.01.
Additional file 2: Figure S2. Potential miRNA regulators of MIEN1.
(A) miRNA identified by miRNA microarray, in silico algorithms and BLAST
showing putative binding sites in the 3′UTR of MIEN1. (B) hsa-miR-940
precursor miRNA – stem-loop-stem structure. (C) Conservation of
miR-940 between different species.
Additional file 3: Figure S3. miR-940 and MIEN1 expression patterns in
various prostate normal and cancer tissues. (A) Pictorial representation of
the miR-940 and MIEN1 expression obtained by in situ hybridization and
immunohistochemical staining. (B) Graphical representation of the
staining intensities for miR-940 (B,i) and MIEN1 (B,ii) based on ImageJ
quantification of the tissues in the tissue microarray containing benign
prostatic hyperplasia(BPH), matched normal(MN) to prostate tumors (PCa)
and metastatic (Mets) tissues. Scale bar: 66.67μm. ***P ≤0.001.
Additional file 4: Figure S4. miR-940 does not alter the cell viability.
(A-B) MTT assay to determine % Viability in (A) PC-3 upon transfection of
Anti-miR-940 and (B) DU-145 upon transfection of Pre-miR-940 or
siMIEN1. **P ≤0.01.
Additional file 5: Figure S5. miR-940 attenuates EMT and promotes
MET. (A) Morphology of colonies formed by Pre-miR-NT or Pre-miR-940
transfected DU-145 cells on adherent plates. (B) Slug mRNA expression in
DU-145 cells transfected with Pre-miR-940 or Pre-miR-NT. (C) E-cadherin
transcript levels in PC-3 cells when transfected with Anti-miR-940 or
Anti-miR-NT. **P ≤0.01; *P ≤0.05.
Additional file 6: Table S1. Predicted pathways altered by miR-940.
(A-B) Pathways potentially affected by common genes predicted by
multiple algorithms as identified by KEGG pathways generated in DAVID
based on the number of genes present in the pathway (A) and the
P-value of the pathways with highest number of genes (B).
Additional File 7. Supplementary materials and methods [51,52].
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